P2B001 is in development as once-daily monotherapy for the treatment of the signs and symptoms early Parkinson’s disease. |
P2B001 is a novel, fixed-dose, once-daily combination of extended-release formulations of pramipexole and rasagiline (0.6/0.75 mg), both components at low doses that are not individually available on the market. |
The combination of pramipexole and rasagiline aims to improve striatal dopaminergic transmission via distinct and potentially synergistic mechanisms. |
Phase 2 data demonstrated significant symptomatic efficacy of P2B001 versus placebo, with a benign safety profile that was similar to placebo. |
Introduction
Introduction to P2B001 and its Components
Chemistry and Pharmacodynamics of P2B001 Components
Pramipexole
Rasagiline
Pharmacokinetics and Metabolism of P2B001
Cmax (pg/ml) | Tmax (h) | AUC0−inf (h*pg/ml) | t½ (h) | |
---|---|---|---|---|
Pramipexole-ER (0.75 mg) + Rasagiline (1 mg) (N = 19) | PPX: 804 ± 222 RAS: 5774 ± 2447 | PPX: 9.1 ± 3.4 RAS: 0.6 ± 0.3 | PPX: 21,451 ± 5388 RAS: 4680 ± 1573 | PPX: 12.2 ± 2.5 RAS: 3.9 ± 1.6 |
P2B001 (0.6/0.75 mg) (N = 19) | PPX: 765 ± 227 RAS: 537 ± 256 | PPX: 7.7 ± 2.9 RAS: 2.5 ± 0.5 | PPX: 18,480 ± 5182 RAS: 3000 ± 715 | PPX: 14.6 ± 3.9 RAS: 12.5 ± 7.3 |
P2B001 Clinical Efficacy
Phase II Clinical Study of Two Doses of P2B001 Versus Placebo
Phase III Clinical Study Comparing P2B001 with its Individual Components
Safety and Tolerability of P2B001
Adverse event | P2B001 Phase II Study [18] | STEP-UP Pramipexole Study [50] | Pramipexole PRAMI-BID Study [52] | ||||||
---|---|---|---|---|---|---|---|---|---|
Placebo | P2B001 (0.6/0.75 mg) | Placebo n = 51 | Pramipexole (1.5 mg) n = 54 | Pramipexole groups combined (1.5–6 mg) N = 213 | Placebo N = 77 | Pramipexole (0.5 mg BID) n = 81 | Pramipexole (0.75 mg BID) n = 73 | Pramipexole (0.5 mg TID) n = 80 | |
Nausea | 1 (2.0) | 10 (20.4) | 5 (9.8) | 9 (16.7) | 42 (19.7) | 8 (10.4) | 18 (22.2) | 11 (15.1) | 15 (18.8) |
Somnolence | 0 | 8 (16.3) | 7 (13.7) | 9 (16.7) | 58 (27.2) | 5 (6.5) | 14 (17.3) | 16 (21.9) | 20 (25.0) |
Dizziness | 4 (8.0) | 5 (10.2) | 10 (19.6) | 10 (18.5) | 39 (18.3) | 7 (9.1) | 9 (11.1) | 5 (6.8) | 9 (11.3) |
Fatigue | 1 (2.0) | 4 (8.2) | 5 (9.8) | 4 (7.4) | 14 (6.8) | 3 (3.9) | 6 (7.4) | 7 (9.6) | 4 (5.0) |
Insomnia | 2 (4.0) | 3 (6.1) | 4 (7.8) | 2 (3.7) | 16 (7.5) | 4 (5.2) | 3 (3.7) | 11 (15.1) | 6 (7.5) |
Orthostatic hypotension | 4 (8.0) | 2 (4.1) | NR | NR | NR | NR | NR | NR | NR |
Headache | 4 (8.0) | 1 (2.0) | 5 (9.8) | 5 (9.2) | 24 (11.3) | 8 (10.4) | 7 (8.6) | 6 (8.2) | 4 (5.0) |
Hallucination | 0 | 0 | 0 | 4 (7.4) | 14 (6.6) | NR | NR | NR | NR |
Constipation | 1 (2.0) | 1 (2.0) | 3 (5.9) | 4 (7.4) | 23 (10.8) | 2 (3.9) | 8 (9.9) | 7 (9.6) | 5 (6.3) |
Confusion | 0 | 0 | 0 | 3 (5.6) | 9 (4.2) | NR | NR | NR | NR |
Abnormal dreams | 0 | 0 | NR | NR | NR | 3 (3.9) | 3 (3.7) | 2 (2.7) | 5 (6.3) |
Peripheral edema | 0 | 0 | NR | NR | NR | 0 | 2 (2.5) | 4 (5.5) | 3 (3.8) |